KM endpoint
Fig. 2. · Panel FULL
Panel FULL 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Dong Ki Lee, Choong-Kun Lee, Hyo Song Kim, Sun Jin Sym, Dae Young Zang, Ki Hyang Kim, Joo Han Lim, Hae Su Kim, Kyung Hee Lee, Heon Yung Gee, Sun Young Rha, Hyunki Kim, Minkyu Jung
Cancer Res Treat 57(3) 770-780
PURPOSE: The nProfiler 1 Stomach Cancer Assay (nProfiler1), designed to predict responses to fluorouracil-based adjuvant chemotherapy, measures the expression of four gastric cancer target genes (GZMB, WARS, SFRP4, and CDX1). The randomized phase III POST trial aimed to compare the efficacies of two adjuvant S-1-based doublet chemotherapies: S-1 plus cisplatin (SP) and S-1 plus docetaxel (DS). This study aimed to validate the nProfiler1 assay using a distinct cohort from the POST trial. MATERIALS AND METHODS: The nProfiler1 assay stratifies patients into three groups (low-risk, intermediate-risk, and high-risk) using the prognostic single-patient classifier and two groups (chemotherapy-benefit and no-benefit) using the predictive single-patient classifier. The nProfiler1 assay was applied to formalin-fixed paraffin-embedded slides obtained from the POST trial. Disease-free survival (DFS) and overall survival (OS), including 5-year survival rates, were calculated for the enrolled patients. RESULTS: Of the 153 patients in the POST trial, 118 were included in the post-hoc analysis. With a median follow-up of 57.9 months, no significant difference in DFS or OS was observed between the SP and DS groups. The prognostic single-patient classifier predicted the OS in the SP group (p=0.043) but not in the DS group (p=0.594). The chemotherapy-benefit group exhibited numerically longer DFS than the no-benefit group in the SP and DS groups. CONCLUSION: The nProfiler1 assay offers valuable insights into the prognosis and efficacy of adjuvant chemotherapy based on fluorouracil plus platinum doublet regimens but not docetaxel-containing regimens. Further validation with larger patient cohorts and different regimens is warranted.
2 个 Figure · 5 个 KM 面板
Fig. 2. Kaplan-Meier analysis of survival stratified by chemotherapy regimen. (A) Kaplan-Meier curve of DFS with 3-year and 5-year DFS. (B) Kaplan-Meier curve of OS with 3-year and 5-year OS. CI, confidence interval.
Fig. 2. · Panel FULL
Panel FULL 是同一 Fig. 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4. Kaplan-Meier analysis of survival stratified by the prognostic single-patient classifier. (A) Disease-free survival of patients classified by the prognostic single-patient classifier in the S-1 plus cisplatin (SP) group. (B) Overall survival of patients classified by the prognostic single-patient classifier in the SP group. (C) Disease-free survival of patients classified by the prognostic single-patient classifier in the docetaxel plus S-1 (DS) group. (D) Overall survival of patients classified by the prognostic single-patient classifier in the DS group. CI, confidence interval; NR, not reached.
Fig. 4. · Panel A
Panel A 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4. · Panel B
Panel B 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4. · Panel C
Panel C 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Fig. 4. · Panel D
Panel D 是同一 Fig. 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。